Stride Arcolab shines as its arm receives US FDA approval for Ifosfamide Injection

29 Nov 2012 Evaluate

Stride Arcolab is currently trading at Rs. 1147.00, up by 24.95 points or 2.22% from its previous closing of Rs. 1122.05 on the BSE.

The scrip opened at Rs. 1158.00 and has touched a high and low of Rs. 1211.05 and Rs. 1117.00 respectively. So far 1, 28,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1,211.05 on 29-Nov-2012 and a 52 week low of Rs. 369.40 on 27-Dec-2011.

Last one week high and low of the scrip stood at Rs. 1211.05 and Rs. 940.00 respectively. The current market cap of the company is Rs. 6,733 crore.

The promoters holding in the company stood at 27.69% while Institutions and Non-Institutions held 54.06% and 18.24% respectively.

Onco Therapies, a wholly owned subsidiary of Stride Arcolab has received ANDA approval for Ifosfamide Injection 50 mg/ mL packaged in 1 gram / 20 mL and 3 grams / 60 mL Single – dose vials.

Ifosfamide is part of the Oncology portfolio licensed to Pfizer for the US market and the product is available for immediate launch.

According to IMS data, the US market for generic Ifosfamide is approximately $15 Million.

Strides Pharma Scien Share Price

942.00 -8.50 (-0.89%)
05-Jul-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1568.85
Dr. Reddys Lab 6536.00
Cipla 1509.40
Zydus Lifesciences 1162.40
Lupin 1769.40
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.